In the face of generic competition, Abbott has asked Irish
biotechnology firm Elan to use its NanoCrystal technology to
develop an "all in one" oral dose formulation combining two
cholesterol drugs, AstraZeneca's Crestor...
EntreMed have entered into a new agreement with Elan, which allows
the clinical-stage pharmaceutical company to utilise Elan's
NanoCrystal Technology to develop the oncology product candidate,
Panzem NCD.
Ireland's Elan has altered its licensing agreement with Roche to
give the Swiss firm expanded access to a technology designed to
improve the performance of drugs.
Ireland's Elan Corp has signed up another heavyweight partner -
Switzerland's Roche - for its NanoCrystals technology, designed to
improve the solubility of drug compounds.
Ireland's Elan Corp has signed up another heavyweight partner -
Janssen - for its NanoCrystals technology, designed to improve the
solubility of drug compounds.